Recommendations Updated for Use of Antiretroviral Tx in HIV

This article originally appeared here.
Share this content:
Recommendations Updated for Use of Antiretroviral Tx in HIV
Recommendations Updated for Use of Antiretroviral Tx in HIV

WEDNESDAY, July 13, 2016 (HealthDay News) -- Recommendations for the use of antiretroviral therapy in HIV infection have been updated for adults, and published in the July 12 issue of the Journal of the American Medical Association, a theme issue on HIV/AIDS.

Huldrych F. Günthard, M.D., from the University Hospital Zurich, and colleagues updated recommendations for the use of antiretroviral therapy in adults with established HIV infection. A panel of experts in HIV research and patient care reviewed data and conducted comprehensive literature searches to develop recommendations.

The researchers note that newer data support the widely accepted recommendation that all individuals with HIV infection with detectable viremia should start antiretroviral therapy, regardless of CD4 cell count. For most patients, recommended optimal initial regimens are two nucleoside reverse transcriptase inhibitors (NRTIs) plus an integrase strand transfer inhibitor. Non-NRTIs or boosted protease inhibitors with two NRTIs are also effective regimens. Convenience, tolerability, simplification, anticipation of potential new drug interactions, and pregnancy or plans for pregnancy are included as reasons for switching therapy. In persons at high risk, daily tenofovir disoproxil fumarate/emtricitabine is recommended for use as preexposure prophylaxis to prevent HIV infection; postexposure prophylaxis should be started as soon as possible after exposure, when indicated.

"Antiretroviral agents remain the cornerstone of HIV treatment and prevention," the authors write. "With these treatment regimens, survival rates among HIV-infected adults who are retained in care can approach those of uninfected adults."

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Illicit Marijuana Use Up in States With Legal Medical Use

Illicit Marijuana Use Up in States With Legal ...

Cannabis use disorder is also rising faster in states with legalization laws

Chromosome Instability Test Prognostic in NSCLC

Chromosome Instability Test Prognostic in NSCLC

Chromosome instability associated with higher risk of relapse, death within 2 years

CDC: Opioid-Related Mortality Rate Might Be Underestimated

CDC: Opioid-Related Mortality Rate Might Be Underestimated

Death certificates from drug-linked infections may not label opioids as possible cause

is free, fast, and customized just for you!

Already a member?

Sign In Now »